Northwestern Mutual Wealth Management Co. Lowers Position in Boston Scientific Corporation $BSX

Northwestern Mutual Wealth Management Co. decreased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 1.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 839,483 shares of the medical equipment provider’s stock after selling 14,862 shares during the period. Northwestern Mutual Wealth Management Co. owned about 0.06% of Boston Scientific worth $35,829,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $5,534,781,000. Primecap Management Co. CA bought a new position in Boston Scientific in the second quarter worth $2,156,233,000. Norges Bank bought a new position in Boston Scientific in the fourth quarter worth $2,199,395,000. Jupiter Topco LLC purchased a new position in Boston Scientific during the second quarter valued at $803,357,000. Finally, Bank of America Corp DE purchased a new position in Boston Scientific during the second quarter valued at $556,026,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $48.05 on Wednesday. The business has a fifty day moving average price of $46.69 and a 200-day moving average price of $56.17. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a market capitalization of $69.64 billion, a PE ratio of 19.45, a PEG ratio of 1.12 and a beta of 0.57. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the business posted $0.75 EPS. Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Boston Scientific

In other news, Director David C. Habiger purchased 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have bought 194,522 shares of company stock worth $9,385,210. Corporate insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on BSX shares. Mizuho reduced their target price on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Argus reissued a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Evercore set a $65.00 price objective on shares of Boston Scientific in a research note on Monday, July 6th. UBS Group cut their price objective on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, TD Cowen reaffirmed a “buy” rating and set a $56.00 target price on shares of Boston Scientific in a research note on Tuesday, August 25th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.